Video Library
BELIEFS IN CML
Does Waiting to Switch to CML Treatments Make Sense?
Should switching CML treatments due to adverse reactions be a last resort? See how switching treatments may help your patients who are struggling and explore the data for SCEMBLIX.
Does Superior Efficacy Have To Mean More Side Effects?
There is a common belief in oncology that associates superior efficacy with more side effects. Is there an opportunity to find a better balance? Explore the efficacy and safety data for SCEMBLIX to see if this balance is possible.
PATIENT EXPERIENCE
What Patients Say About Their Experience
Patients who are taking SCEMBLIX talk about their CML treatment journey and share their experiences.
EXPERT PERSPECTIVES
Clinical Evidence for a Different Approach to Treating Patients With Ph+ CML-CP.
Luke Akard, MD, from the Indiana Blood and Marrow Transplantation in Indianapolis, discusses the clinical trial data supporting the approval of SCEMBLIX in the treatment of certain patients with Ph+ CML-CP.
UNMET NEEDS IN CML
Unmet Needs in CML
Jorge Cortes, MD, director of the Georgia Cancer Center, outlines why SCEMBLIX may help patients who have suboptimal responses and/or intolerance to 2 or more prior TKIs, or who have the T315I mutation, achieve responses.
DOSING AND ADMINISTRATION
Dosing and Administration
Jorge Cortes, MD, director of the Georgia Cancer Center, highlights the different SCEMBLIX dose schedules for each of its indications and discusses dose modification and management recommendations.